NEW YORK (GenomeWeb News) – Cellectis today said that it has acquired all of the assets of Cyto Pulse Sciences, which specializes in electroporation technology and equipment, for $2.2 million in cash.
The acquisition provides Paris-based Cellectis with a range of electroporation instruments for in vivo and in vitro delivery of nucleic acids and proteins; Pulse Agile, an electroporation technology for use with Cellectis' meganuclease platform; and recurring license revenue from Cyto Pulse's Hybrimune technology, which provided more than $600,000 in licensing revenue in 2009, and is available through Cellectis Bioresearch.
"As we announced last year, part of our development strategy is to acquire businesses that complement our existing meganuclease platform and that can be leveraged across all aspects of our business, from research through to therapeutics," Cellectis CEO Andre Choulika said in a statement. "We saw such an opportunity in the technologies at Cyto Pulse Sciences and look forward to unlocking the value of these assets."
Maryland-based Cyto Pulse filed for Chapter 7 bankruptcy in June, seeking to liquidate its assets.